UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
Thursday, August 20, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: UroGen has entered a strategic collaboration with IntraGel, granting it a research license and exclusive options to develop up to three oncology products using IntraGel's SRGel platform. The agreement also includes an option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head and neck cancer. This partnership is expected to bolster UroGen's oncology pipeline significantly.
Market Sentiment Analysis
POSITIVE FACTORS
UroGen gains access to IntraGel's innovative SRGel platform.
Collaboration aims to expand UroGen's oncology pipeline.
Exclusive options for three oncology products enhance development potential.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head
Frequently Asked Questions
What is the focus of UroGen's collaboration with IntraGel?
The collaboration focuses on developing oncology products using IntraGel's SRGel platform.
How many oncology products can UroGen develop with IntraGel?
UroGen can develop up to three oncology products through this collaboration.
What rights does UroGen have regarding TumoCure?
UroGen has an exclusive option to acquire worldwide rights to TumoCure.
What type of therapy is TumoCure?
TumoCure is an investigational therapy for advanced head and neck cancer.